MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from follow-on
offering, net of issuance...
$138,390K
Proceeds from research
and development...
$12,000K
Net proceeds from
stock option...
$781K
Proceeds from espp
offerings
$341K
Net cash provided by
financing activities
$151,512K
Net change in cash,
cash equivalents,...
-$119,815K
Canceled cashflow
$151,512K
Stock-based compensation
expense
$29,268K
Non cash lease
expense
$9,698K
Depreciation expense
$7,321K
Prepaid expenses and
other current assets
-$4,545K
Accounts payable
$996K
Maturities of investments
$95,781K
Sales of investments
related party
$5,400K
Net cash used in
operating activities
-$162,564K
Canceled cashflow
$51,828K
Net cash (used in)
provided by investing...
-$108,763K
Total other income,
net
$7,208K
Total revenue
$4,632K
Canceled cashflow
$101,181K
Net loss
-$201,142K
Canceled cashflow
$11,840K
Lease liability
-$5,362K
Deferred revenue related
party
-$4,359K
Amortization of premiums and
discount on short-term...
$1,937K
Accrued expenses and
other current...
-$1,160K
Change in fair value of
short-term investment ...
$432K
Purchases of investments
$205,413K
Purchases of property and
equipment
$4,531K
Total operating
expenses
$212,982K
Back
Back
Cash Flow
source: myfinsight.com
Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. (PRME)